Singapore, March 21 -- SK bioscience has shipped approximately 440,000 doses of SKYCellflu to Biogenetech in Thailand from its vaccine manufacturing facility 'L HOUSE' in Andong, South Korea.

The vaccine, the company's self-developed cell-cultured influenza vaccine, contains the recommended composition of influenza virus for use in the 2024 Southern Hemisphere influenza season announced by the World Health Organization (WHO). Starting with the export to Thailand, SK bioscience expects to extend its sales not only in the Southeast Asian market but also in the Southern Hemisphere market.

Thailand is affected by both the WHO's Northern and Southern Hemisphere flu vaccination guidelines due to its elongated geography from north to south. Re...